Monosialotetrahexosylganglioside

DRUG2 trials

Sponsors

Sun Yat-sen University, Alliance for Clinical Trials in Oncology

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Chemotherapy-Induced Peripheral NeuropathyMetastatic Breast CarcinomaMultiple Myeloma

Phase 2

Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy

Sun Yat-sen UniversityMultiple Myeloma

Start: 2014-04-30End: 2018-04-30Target: 100Updated: 2014-11-19

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

Active, not recruitingNCT05751668

Alliance for Clinical Trials in OncologyAnatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma

Start: 2023-11-02End: 2032-03-15Updated: 2026-09-16

Related Papers

Phase 2 Trial of Concurrent Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-Induced Peripheral Neuropathy in Patients of Multiple Myeloma

Blood2015-12-03